Hurler Syndrome Treatment Market is set for steady growth to US$ 529.34 million by 2033 | Key Players:- Orchard Therapeutics, JCR Pharmaceuticals, Immusoft

The Global Hurler Syndrome Treatment Market reached US$ 377.65 million in 2024 and is expected to reach US$ 529.34 million by 2033, growing at a CAGR of 3.9% during the forecast period 2025-2033.

Market growth is driven by the increasing diagnosis of Hurler Syndrome through newborn screening programs, rising awareness among healthcare professionals and families, and growing adoption of enzyme replacement therapy and hematopoietic stem cell transplantation. Additionally, advancements in gene therapy research, improving access to rare disease treatment, supportive regulatory initiatives, and favorable reimbursement policies are further supporting market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/hurler-syndrome-treatment-market?pratik

United States: Key Industry Developments
✅ June 2025: Orchard Therapeutics completed the Phase 3 HURCULES clinical trial for OTL-203, a gene therapy for Hurler syndrome (MPS-IH), demonstrating superior efficacy over standard HSCT in neurological and skeletal outcomes for early-treated patients.
​
✅ May 2025: REGENXBIO received FDA priority review for clemidsogene lanparvovec (RGX-121), advancing treatment options for MPS disorders including insights applicable to Hurler syndrome through accelerated approvals.
​
✅ February 2025: Orchard Therapeutics presented proof-of-concept data for OTL-203 gene therapy at the WORLDSymposium, highlighting improved clinical outcomes in Hurler patients compared to traditional therapies.
​
Asia Pacific / Japan: Key Industry Developments
✅ June 2025: MEDIPAL Holdings and JCR Pharmaceuticals secured European Commission Orphan Drug Designation for JR-446, an investigational therapy for MPS type IIIB, with potential cross-regional implications for Hurler syndrome pipelines in Japan.
​
✅ July 2025: Market reports noted rising adoption of enzyme replacement therapy (ERT) in Asia Pacific for MPS Type 1 (Hurler syndrome), driven by improved diagnostics and biotechnology advancements amid growing rare disease awareness.
​
✅ March 2025: Ongoing research emphasized ERT and gene therapy progress for MPS I (Hurler syndrome) in Japan, supported by regional healthcare investments and clinical trial expansions for better patient outcomes.

Market Segmentation Analysis:
By Treatment Type: ERT Dominates
Enzyme replacement therapy (ERT) leads the MPS treatment market, holding the dominant share in 2024 due to approved products like Aldurazyme for MPS I (Hurler).​
Others, including hematopoietic stem cell transplants (HSCT) and emerging gene therapies, capture the remaining share, with HSCT favored for severe pediatric cases but limited by donor availability.​

By Route of Administration: Intravenous Prevails
Intravenous administration commands the majority revenue share, as key ERTs like Aldurazyme and Elaprase for MPS types are delivered this way.​
Intracerebroventricular (ICV) options hold a smaller portion, mainly for select therapies like Hunterase, with growth expected from expanded approvals.​

By End-User: Hospitals at 61.4%
Hospitals hold 61.4% share in 2025 for MPS treatments, driven by need for specialized IV administration and monitoring in acute settings.​
Specialty clinics and others follow, gaining from increased rare disease centers and home infusion trends.

Purchase this report before year-end and unlock an exclusive 30% discount:https://www.datamintelligence.com/buy-now-page?report=hurler-syndrome-treatment-market?pratik (Purchase 2 or more Reports and get 50% Discount)

Growth Drivers:
Increasing Awareness and Early Diagnosis
Better education among healthcare professionals and expanded newborn screening programs are enabling earlier detection of Hurler syndrome. Early diagnosis often leads to prompt treatment initiation, which improves patient outcomes and increases demand for therapies.

Advancements in Therapeutic Options
Innovation in treatment modalities especially enzyme replacement therapies (ERT) and emerging gene therapies is a significant growth driver. These advances are expanding the available therapeutic choices, improving clinical efficacy, and attracting further investment in the market.

Supportive Regulatory and Orphan Drug Policies
Orphan drug designations, accelerated approval pathways, and incentives for rare disease R&D encourage pharmaceutical companies to develop and bring novel treatments to market. This regulatory support helps accelerate commercialization and reduces time-to-market for new therapies.

Growing Healthcare Infrastructure and Expenditure
Increased healthcare spending and improved medical infrastructure especially in emerging regions such as Asia Pacific are enabling broader access to specialized diagnostics and treatments for rare genetic disorders like Hurler syndrome.

Rising Prevalence and Identification of Unmet Medical Need
With improved diagnostic capabilities and genetic screening, more cases of Hurler syndrome are being identified globally. The expanding recognized patient population highlights the need for effective treatments, thus stimulating market growth.

Regional Insights:
North America commands the largest share of the Hurler Syndrome Treatment Market, estimated at around 45% in recent assessments, driven by advanced healthcare infrastructure, high prevalence of rare genetic disorders, substantial R&D investments in enzyme replacement and gene therapies, and favorable orphan drug policies in the US and Canada.​

Europe follows as the second-largest region, benefiting from stringent medical regulations, rising adoption in countries like Germany, France, and the UK, and growing awareness of early diagnosis and hematopoietic stem cell transplantation, though exact shares vary by report amid steady market expansion.​

Asia Pacific ranks third in market share, yet exhibits the fastest growth potential with high CAGRs in nations such as China, India, and Japan, fueled by increasing healthcare investments, government subsidies for rare disease treatments, and expanding access to specialized pediatric care.

Speak to Our Analyst and Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/hurler-syndrome-treatment-market?pratik

Key Players:
-Orchard Therapeutics, JCR Pharmaceuticals, Immusoft, Armagen, Regenxbio, Paradigm Biopharmaceuticals Ltd, Sanofi and BioMarin

Key Highlights (Top 5 Key Players) :
Orchard Therapeutics
Develops OTL-203, a gene therapy for MPS-IH (Hurler Syndrome), using hematopoietic stem cells to produce IDUA enzyme. Completed last patient dosing in the HURCULES registrational trial versus HSCT standard care in 2025.​

BioMarin
Co-develops Aldurazyme (laronidase), the FDA-approved enzyme replacement therapy for Hurler and Hurler-Scheie forms of MPS I since 2003. Addresses somatic symptoms but limited CNS penetration; generated $321M sales in 2024.​

Sanofi
Partners with BioMarin on Aldurazyme (laronidase) ERT for MPS I patients with Hurler/Hurler-Scheie forms, reducing glycosaminoglycans in somatic tissues. Weekly IV infusions; does not treat CNS manifestations effectively.​

Regenxbio
Advances RGX-111, an AAV gene therapy candidate for Hurler Syndrome (MPS I), in early clinical testing. Licensed Asia rights to Nippon Shinyaku in 2025; focuses on one-time CNS-penetrating treatment.​

Immusoft
Develops ISP-001, an autologous B cell therapy engineered to produce alpha-L-iduronidase for MPS I (Hurler). Phase I trial showed encouraging pharmacodynamic results in first patient in 2025; Orphan Drug status.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?pratik

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele

This release was published on openPR.